Fahai Chen et al. identified 5 immune-related hub genes associated with poor prognosis and response to trastuzumab treatment in breast cancer patients, with NR3C1 being one of them (Chen and Fang, 2022). This evidence concerns the gene NR3C1 and breast carcinoma.